Ligand Pharmaceuticals Incorporated most recently reported annual revenue of $268.0M, net profit of $124.0M. Revenue grew at an average annual rate of 10.3% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Ligand Pharmaceuticals Incorporated: Revenue rose from $109.0M in 2016 to $268.0M in 2025, a change of +145.9% over 9 years; net profit was positive in 6 of 10 reported years; operating margin moved from 40.3% to 17.6%, a shift of -22.7 percentage points; the most recent year shows net profit of $124.0M.
Income Statement — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Revenue
$109.0M
$141.0M
$251.0M
$120.0M
$164.0M
$242.0M
$196.0M
$131.0M
$167.0M
$268.0M
Operating Expenses
$65.0M
$73.0M
$88.0M
$-687.0M
$126.0M
$138.0M
$193.0M
$119.0M
$190.0M
$221.0M
Operating Profit
$44.0M
$68.0M
$164.0M
$807.0M
$38.0M
$104.0M
$3.0M
$12.0M
$-23.0M
$47.0M
Operating Margin
40.3%
48.3%
65.1%
671.0%
22.9%
43.0%
1.6%
9.1%
-13.5%
17.6%
Other Income
$-36.0M
$-11.0M
$10.0M
$-10.0M
$-36.0M
$-32.0M
$33.0M
$52.0M
$25.0M
$112.0M
Interest
$12.0M
$11.0M
$48.0M
$36.0M
$27.0M
$20.0M
$2.0M
$1.0M
$3.0M
$5.0M
Depreciation
$11.0M
$13.0M
$17.0M
$44.0M
$28.0M
$51.0M
$43.0M
$37.0M
$35.0M
$34.0M
Profit Before Tax
$8.0M
$57.0M
$173.0M
$797.0M
$1.0M
$72.0M
$36.0M
$64.0M
$3.0M
$159.0M
Tax
$129.7M
$78.1M
$17.3M
$21.0M
$-410.7M
$-5.7M
$114.5M
$15.5M
$260.1M
$21.7M
Net Profit
$-2.0M
$13.0M
$143.0M
$629.0M
$-3.0M
$57.0M
$-33.0M
$52.0M
$-4.0M
$124.0M
EPS
$-0.08
$0.53
$5.96
$31.85
$-0.18
$3.34
$-1.98
$2.94
$-0.22
$6.13
Dividend Payout
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Results — Last 12 Quarters (USD millions)
8 duplicate period labels in the source data were collapsed.
Metric
Sep '23
Dec '23
Mar '24
Jun '24
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Revenue
$33.0M
$28.0M
$31.0M
$42.0M
$52.0M
$43.0M
$45.0M
$48.0M
$115.0M
$60.0M
$52.0M
$64.0M
Operating Expenses
$30.0M
$31.0M
$28.0M
$61.0M
$49.0M
$52.0M
$82.0M
$39.0M
$61.0M
$40.0M
$34.0M
$55.0M
Operating Profit
$3.0M
$-3.0M
$3.0M
$-19.0M
$3.0M
$-10.0M
$-36.0M
$8.0M
$55.0M
$20.0M
$17.0M
$9.0M
Operating Margin
9.4%
-11.9%
9.7%
-46.0%
6.1%
-22.5%
-79.9%
17.7%
47.6%
33.6%
33.6%
13.5%
Interest
$0
$0
$0
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
$2.0M
$2.0M
$2.0M
Profit Before Tax
$-12.0M
$17.0M
$113.0M
$-65.0M
$-6.0M
$-39.0M
$-50.0M
$11.0M
$141.0M
$57.0M
$-24.0M
$64.0M
Tax
$15.4M
$-6.4M
$24.1M
$20.6M
$-13.1M
$20.7M
$15.4M
$56.8M
$16.9M
$21.1M
$45.0M
$24.6M
Net Profit
$-10.0M
$18.0M
$86.0M
$-52.0M
$-7.0M
$-31.0M
$-42.0M
$5.0M
$117.0M
$45.0M
$-13.0M
$49.0M
EPS
$-0.74
$1.03
$4.75
$-2.88
$-0.39
$-1.64
$-2.21
$0.24
$5.68
$2.12
$-0.67
$2.22
Over the 10 years reported for Ligand Pharmaceuticals Incorporated, borrowings increased from $213.0M in 2016 to $451.0M in 2025, cash stood at $175.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 22.49 times.
Balance Sheet — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
$602.0M
$671.0M
$1.3B
$1.5B
$1.4B
$1.3B
$763.0M
$787.0M
$942.0M
$1.6B
Current Assets
$163.0M
$237.0M
$871.0M
$1.1B
$501.0M
$465.0M
$264.0M
$237.0M
$332.0M
$832.0M
Cash
$141.0M
$202.0M
$718.0M
$72.0M
$48.0M
$20.0M
$45.0M
$23.0M
$72.0M
$175.0M
Inventory
$2.0M
$4.0M
$7.0M
$7.0M
$26.0M
$27.0M
$13.0M
$24.0M
$14.0M
$9.0M
Receivables
$18.0M
$26.0M
$56.0M
$42.0M
$59.0M
$92.0M
$35.0M
$39.0M
$42.0M
$61.0M
Fixed Assets
$2.0M
$4.0M
$5.0M
$18.0M
$37.0M
$33.0M
$27.0M
$25.0M
$25.0M
$11.0M
Capital Work in Progress
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Investments
$8.0M
$6.0M
$647.0M
$998.0M
$364.0M
$322.0M
$170.0M
$259.0M
$195.0M
$742.0M
Other Assets
$277.0M
$315.0M
$306.0M
$95.0M
$190.0M
$106.0M
$106.0M
$103.0M
$105.0M
$102.0M
Total Liabilities
$231.0M
$252.0M
$700.0M
$728.0M
$653.0M
$476.0M
$165.0M
$86.0M
$111.0M
$543.0M
Current Liabilities
$227.0M
$239.0M
$82.0M
$17.0M
$100.0M
$42.0M
$99.0M
$17.0M
$37.0M
$37.0M
Borrowings
$213.0M
$225.0M
$636.0M
$650.0M
$456.0M
$324.0M
$88.0M
$6.0M
$7.0M
$451.0M
Other Liabilities
$18.0M
$28.0M
$64.0M
$77.0M
$196.0M
$152.0M
$77.0M
$80.0M
$104.0M
$92.0M
Equity
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Reserves
$371.0M
$419.0M
$561.0M
$767.0M
$710.0M
$821.0M
$597.0M
$701.0M
$830.0M
$1.0B
For Ligand Pharmaceuticals Incorporated, operating cash flow was positive in 9 of 10 reported years; free cash flow in the latest year was $49.0M; free cash flow was positive in 8 of 10 years; financing activities used $25.0M in the latest year, which covers debt repayment, dividends and buybacks.